Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. While talking about the company, Cramer said that investors are not “supposed to buy drug stocks” when the Fed is cutting rates. He remarked: “Not that long ago, pretty much everybody assumed that the next non-tech stock to cross the trillion-dollar threshold would be the stock of Eli Lilly. Why not? They’ve developed a weight loss and diabetes wonder drug with incredible prospects… Right now, Lilly’s market capitalizatio ...

Core Viewpoint - The article discusses the significant impact of the drug Tirzepatide (Zepbound) on weight loss and its implications for the food industry, highlighting its effectiveness and the growing demand since its approval by the FDA in late 2023 [4][6][12]. Group 1: Drug Efficacy and Impact - After using Tirzepatide, patients reportedly reduce their daily caloric intake by approximately 800 calories, equivalent to one meal [4][5]. - In clinical trials, patients using the highest dosage of Tirzepatide lost an average of 22.5% of their body weight [6]. - A study conducted by Fudan University confirmed that Tirzepatide is safe and effective for weight loss in Chinese adults, with participants losing an average of 16.1 kg over 52 weeks [9][10]. Group 2: Market Dynamics and Competition - Tirzepatide belongs to the rapidly growing GLP-1 drug class, which mimics gut hormones to regulate blood sugar and suppress appetite [8]. - Major competitors in the GLP-1 space include Novo Nordisk, which produces Ozempic and Wegovy, both containing the active ingredient Semaglutide [12]. - The popularity of GLP-1 drugs has led to increased stock prices for companies like Eli Lilly, but concerns remain about potential negative impacts on the food and beverage industry [14].

Core Insights - The global GLP-1 market is experiencing significant attention due to its multi-billion-dollar potential, primarily led by Novo Nordisk and Eli Lilly with their respective products targeting type II diabetes and obesity [1] Competitive Landscape - Eli Lilly and Novo Nordisk have intensified competition, with Eli Lilly's orforglipron showing superior results in A1C and body weight reduction compared to Novo Nordisk's Rybelsus, although orforglipron had higher discontinuation rates due to gastrointestinal side effects [2] - Novo Nordisk's Ozempic demonstrated a 23% reduction in the risk of major adverse cardiovascular events (MACE) compared to Eli Lilly's Trulicity, along with a 25% reduction in a broader composite endpoint [4][10] - Novo Nordisk received EU approval to add cardiovascular benefits to the Rybelsus label, with a 14% reduction in MACE, while FDA review for a similar label expansion is pending [5] Financial Performance - Eli Lilly's Mounjaro and Zepbound generated combined sales of $14.7 billion in the first half of 2025, accounting for 52% of the company's total revenues, indicating a significant market share impact on Novo Nordisk [6] - Novo Nordisk's stock has underperformed, losing 28.1% year-to-date compared to the industry's 0.5% growth [8] Stock Valuation and Estimates - Novo Nordisk's shares are trading at a forward price/earnings ratio of 15.43, higher than the industry average of 14.83, but significantly below its five-year mean of 29.25 [12] - Earnings estimates for 2025 have decreased from $3.98 to $3.85 per share, and for 2026 from $4.56 to $4.07 over the past 60 days, indicating a downward trend in expectations [15]

E-commerce and data centre company Amazon has agreed to promote SME sellers on its platform for exports aggressively. It also agreed to promote the products of women entrepreneurs.“Amazon will also work with the government to establish 100 relaxation centres for gig workers across Hyderabad. These air-conditioned centres will have all facilities, including parking, charging for mobile devices, resting areas, and spaces for taking naps,” a statement from the Chief Minister’s Office said here on Friday.The de ...

Plus, solar cars, Meta's new glasses and AI financial agents, in this edition of The Future of Everything newsletter. ...

Core Insights - Eli Lilly's orforglipron shows superior glycemic control compared to oral semaglutide in recent clinical trials [1][2] - The ACHIEVE-3 trial results indicate a significant reduction in HbA1c levels and weight loss for orforglipron users [2][3] - The oral GLP-1 drug market is expanding, with increasing interest from Chinese companies in developing oral formulations [4][5] Group 1: Clinical Trial Results - The ACHIEVE-3 trial demonstrated that the highest dose of orforglipron resulted in a 2.2% reduction in HbA1c, compared to a 1.4% reduction for oral semaglutide [2] - Participants using orforglipron lost an average of 8.9 kg (9.2%), while those on oral semaglutide lost 5.0 kg (5.3%), representing a relative improvement of 73.6% [2] - Orforglipron users showed clinical improvements in cardiovascular risk factors, including non-HDL cholesterol and triglycerides [2] Group 2: Market Dynamics - Oral semaglutide's revenue grew from $0.07 billion in 2019 to $3.38 billion in 2024, with a compound annual growth rate of 239.5% [4] - The preference for oral medications over injections is evident, with 39.7% of surveyed individuals favoring oral treatments [5] - Chinese companies are accelerating their development of oral GLP-1 drugs, with several candidates in late-stage clinical trials [5]

Core Viewpoint - The approval of Masitide, a dual receptor agonist for GCG/GLP-1, marks a significant milestone for the company and the diabetes treatment landscape in China [1] Group 1: Product Approval - Masitide has received approval from the National Medical Products Administration for use in blood sugar control in adult patients with type 2 diabetes [1] - This product is the first globally approved GCG/GLP-1 dual receptor agonist, developed in collaboration with Eli Lilly [1] Group 2: Market Potential - Masitide was previously approved in June 2025 for long-term weight management in adult patients in China [1]

Core Viewpoint - Eli Lilly's orforglipron shows significantly better glycemic control compared to oral semaglutide in the phase III clinical trial "ACHIEVE-3" [2][3] Group 1: Clinical Trial Results - In the ACHIEVE-3 trial, the highest dose of orforglipron resulted in a 2.2% reduction in HbA1c, while the highest dose of oral semaglutide resulted in a 1.4% reduction [3] - Participants using the highest dose of orforglipron lost an average of 8.9 kg (9.2%), compared to a 5.0 kg (5.3%) loss for those on oral semaglutide, representing a relative improvement of 73.6% [3] - Orforglipron users showed clinically meaningful improvements in several cardiovascular risk factors, including non-HDL cholesterol, systolic blood pressure, and triglycerides [3] Group 2: Market Context and Competitors - Oral semaglutide is currently the only approved oral GLP-1 drug for type 2 diabetes, with revenue growth from $0.07 billion in 2019 to $3.383 billion in 2024, reflecting a compound annual growth rate of 239.5% [5] - Novo Nordisk has submitted a weight loss indication application for oral semaglutide, which has shown near-injection efficacy in late-stage trials [5] - The development of oral GLP-1 formulations is challenging, with two main directions: oral peptides and oral small molecules, each facing unique challenges [5][6] Group 3: Industry Trends - There is a growing preference for oral medications over injections, with 39.7% of surveyed individuals indicating a preference for oral treatments [6] - The complexity and unpredictability of side effects in oral small molecules present additional challenges, but the higher technical barriers in oral GLP-1 development may reduce competition [6] - Chinese companies are accelerating their development of oral GLP-1 drugs, with several candidates in late-stage clinical trials [6]

Group 1: Diabetes Market Overview - Diabetes is a chronic health condition characterized by long-term high blood sugar levels, affecting a significant portion of the global population. In 2021, 537 million adults aged 20-79 were diagnosed with diabetes, projected to rise to 643 million by 2030 [1] - The global diabetes drug market is valued at $88.32 billion in 2024, expected to grow to $1001.48 billion by 2025 and reach $2338.4 billion by 2032, with a compound annual growth rate (CAGR) of 12.7% during the forecast period [1] - The increasing prevalence of diabetes is driving demand for treatment drugs, leading to intensified development efforts by pharmaceutical companies [1] Group 2: Eli Lilly - Eli Lilly's China division merged its Immunology and Oncology divisions into a new "Immunology and Oncology Division," effective October 1, 2025, with a new leader appointed [2] - In the first half of 2025, Eli Lilly's revenue in China reached $917 million, a 19% year-on-year increase, driven by a 1.6-fold increase in sales of GLP-1 drugs [2] - Eli Lilly's total revenue for the first half of 2025 was $28.2862 billion, a 41% increase from the previous year, with diabetes and weight loss drugs contributing nearly half of its revenue [3] Group 3: Novo Nordisk - Novo Nordisk announced a global transformation plan to simplify its organizational structure and refocus resources on growth opportunities in diabetes and obesity [4] - The company plans to cut approximately 9,000 jobs globally, representing about 11% of its workforce, with an expected annual cost saving of 8 billion Danish Krone by the end of 2026 [5] - In the first half of 2025, Novo Nordisk reported revenue of 154.944 billion Danish Krone (approximately 173.7 billion Yuan), an 18% increase at fixed exchange rates, with significant contributions from GLP-1 products [6] Group 4: Merck & Co. - Merck & Co. announced a restructuring of its diabetes division, merging it with other mature product lines into an Entrepreneurial Business Unit, indicating a decline in the diabetes product lifecycle [7] - The company reported total revenue of $31.3 billion for the first half of 2025, a 2% decrease, with a significant drop in revenue from its diabetes products in China [8] - Merck plans to implement a cost-saving initiative aiming to save $3 billion annually by 2027, including a workforce reduction of approximately 6,000 employees [9] Group 5: Sanofi - Sanofi ceased the promotion of its new lipid-lowering drug in China due to global supply issues and strategic adjustments in its cardiovascular market [10] - In the first half of 2025, Sanofi's revenue in China was €1.388 billion (approximately 11.7 billion Yuan), showing a slight growth of 0.1% [10] - Sanofi has shifted its focus from diabetes to immunology and inflammation, attempting to transform from a diabetes giant to a leader in the immunology sector [11]

Core Viewpoint - Novo Nordisk's Ozempic shows a 23% lower risk of heart attack, stroke, and death compared to Eli Lilly's Trulicity, significantly impacting the competitive landscape in diabetes and weight loss medications [1][2]. Group 1: Study Results - A Medicare study involving nearly 60,000 patients indicates that patients using Ozempic have a 23% lower risk of heart-related issues compared to those using Trulicity [2]. - Novo Nordisk presented these findings at the European Association for the Study of Diabetes meeting, highlighting the importance of this data in countering Eli Lilly's market share gains with Mounjaro and Zepbound [2][5]. Group 2: Market Impact - Following the announcement of the study results, Novo Nordisk's stock surged over 7%, marking its largest increase in a month, after a 56% decline over the past year due to various clinical and commercial setbacks [2]. - The competitive landscape is intensifying, with both companies releasing comparative data to persuade healthcare providers to choose their products [5]. Group 3: Ongoing Research and Development - Novo Nordisk is advancing a higher dose of Rybelsus, which has shown stronger weight loss effects and has been approved in Europe for diabetes treatment [6]. - Eli Lilly's Mounjaro has shown similar efficacy to Trulicity in reducing heart-related risks, but this trial is not directly comparable to the Ozempic-Trulicity study, which reflects real-world outcomes [6]. Group 4: Physician Considerations - Physicians are encouraged to consider individual patient circumstances when choosing between Mounjaro and Trulicity, as Mounjaro offers additional benefits such as greater weight loss and improvements in obesity-related conditions [7]. - Novo Nordisk focuses on demonstrating its drugs' effectiveness in real-world settings, including studies on its weight loss injection Wegovy's ability to suppress intrusive food thoughts [7].